Trust Company of Vermont’s Lifecore Biomedical LFCR Stock Holding History

Trust Company of Vermont’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-300	Closed	-$4K	–	754
2015 Q4	$4K	Hold	300	–	–	﹤0.01%	701
2015 Q3	$4K	Hold	300	–	–	﹤0.01%	718
2015 Q2	$4K	Buy	+300	New	+$4.33K	﹤0.01%	743

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

NIMC

NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Trust Company of Vermont's LFCR Position: Q1 2016 in Review

Trust Company of Vermont sold out of Lifecore Biomedical (LFCR) in Q1 2016, closing a stake of 300 shares — an estimated $4K sold.

Trust Company of Vermont first reported a position in LFCR in Q2 2015 and held it in 3 quarters. The position peaked at $4K in Q4 2015. 96 funds tracked by Wall St. Rank hold LFCR as of Q1 2016.

Trust Company of Vermont reported no remaining Lifecore Biomedical position as of Q1 2016 after selling out during the quarter.
Trust Company of Vermont sold 300 Lifecore Biomedical shares in Q1 2016, an estimated $4K.
Trust Company of Vermont first reported a position in Lifecore Biomedical in Q2 2015 and held it in 3 quarters.
Trust Company of Vermont's Lifecore Biomedical position peaked at $4K in Q4 2015.
96 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2016.

Based on Trust Company of Vermont's 13F filing for Q1 2016, filed 27 Apr 2016.